The Abacus Medicine Group faced challenging market conditions in 2021 as millions of
treatments were postponed due to COVID-19. Today, the Group announces revenue growth
of 42% to EUR 941 million. Organic growth was 19%, when adjusted for the effect of the
Pluripharm business being included in the numbers with 12 months in 2021 against 5
months in 2020. EBITDA of EUR 16.6 million was a also new record for the company.
